📊 Adjuvant therapy in low-grade endometrioid carcinoma with adnexal involvement? A retrospective SEER study reports 70.6% 5-year OS without adjuvant therapy, highlighting the need for individualized care.
Read more: doi.org/10.3802/jgo.2026.37.…
#EndometrialCancer
1
186
📢New in #JGO: In 295 Indian women 🇮🇳, first-void urine and self-collected vaginal swabs showed favorable performance for high-risk #HPV testing. First-void urine may offer a non-invasive, acceptable option to help expand #CervicalCancer screening.
🔗doi.org/10.3802/jgo.2026.37.…
2
228
How is hereditary breast and #OvarianCancer care delivered across #Japan? A nationwide survey of 248 institutions found wide variation in testing practices, #GeneticCounseling resources, and post-RRSO management - including STIC.
Read the JGO article: doi.org/10.3802/jgo.2026.37.…
📑JGO Article Alert
Could #surgery improve outcomes in recurrent low-grade serous #OvarianCancer? 🔎 A 152-patient, 31-center study linked secondary #cytoreduction to longer #survival (adjusted HR 0.28; p<0.001), with complete resection in 92%.
➡️doi.org/10.3802/jgo.2026.37.…
3
180
📢New in #JGO
Can neoadjuvant chemotherapy followed by radical surgery be an option for node-positive locally advanced #CervicalCancer?
In 97 patients with FIGO IIIC1–2 disease:
🔹5-year OS: 61.1%
🔹5-year PFS: 58.5%
➡️doi.org/10.3802/jgo.2026.37.…⬅️
#GynecologicOncology #CCRT
2
402
📢New in #JGO: In stage IIICr #CervicalCancer without parametrial involvement, primary #chemoradiation showed better #PFS than radical #hysterectomy with lymphadenectomy, especially for tumors ≥4 cm
➡️ejgo.org/DOIx.php?id=10.3802…
🌟JGO Best Reviewer Recognition 2026🌟
Congratulations to our outstanding reviewers:
🏅 Jumpei Ogura, M.D., Ph.D.
Kyoto University
🏅 Yoko Furutake, M.D., Ph.D.
Rakuwakai Otowa Hospital
Thank you for your valuable contributions to #JGO🙏
#GynecologicOncology #JSGO2026
🤖 Made with AI
1
177
🆕 New Article in JGO
📊 In a prospective UK #biobank analysis, higher triglyceride-glucose (TyG) and TyG-BMI indices were associated with increased #EndometrialCancer risk, highlighting the potential role of #insulin resistance.
🔗ejgo.org/DOIx.php?id=10.3802…
1
127
New in #JGO: #SWOG S1609 DART reports #VaginalCancer subcohort results for #ipilimumab + #nivolumab.
In 7 patients, dual ICI showed #ORR 29% and CBR 43%, with durable responses and no new safety signals. 🧬
Read➡️ejgo.org/DOIx.php?id=10.3802…
New article in #JGO: Fan & Fu map cross-country inequalities in the global burden of #CervicalCancer using GBD 2021 data and frontier analysis. Disparities are widening in low-SDI regions.
➡️ejgo.org/DOIx.php?id=10.3802…
127
🆕Pediatric non-gestational choriocarcinoma (PNGC) remains a rare & aggressive disease🧬
In a 74-patient review, comprehensive multimodal therapy improved #survival, while single/no treatment was linked to poor outcomes (3-year OS: 50.8%) ⚕️📊🎯
🔗ejgo.org/DOIx.php?id=10.3802…
55
🧬New Review in #JGO! Discover the evolving concepts of #FallopianTube lesions and their role in #OvarianCancer pathogenesis. From SCOUTs to STICs, explore key histopathological & molecular insights🔬
Read here 👉 ejgo.org/DOIx.php?id=10.3802…
Trastuzumab deruxtecan (#TDXd) shows durable responses in HER2+ #GynecologicCancers💪, with highest benefit in IHC 3+ tumors. ORRs: #endometrial 57.5%, #cervical 50%, #ovarian 45% 📊. Safety profile consistent✅.
Read more: ejgo.org/DOIx.php?id=10.3802…
#GynOnc #HER2 #Oncology
63
🎓Inaugural #ASYGO session at #ASGO2025! Young #GynecologicOncologists discussed
Rapid #MIS growth but training gaps remain
Limited hands-on & #robotic experience
Call for standardized, competency-based curricula & cross-border mentorshipship
Read more: ejgo.org/DOIx.php?id=10.3802…
101
📣Excited to share that #ASGO2026 - the Annual Meeting of the Asian Society of Gynecologic Oncology - is happening Dec 4-6 at the #Shanghai International Conference Center in #China! 🇨🇳
Visit 👉 apollo10-asgo2026.org/
#ASGO @ASGOLearninghub @KSGO_org #JSGO #GynecologicOncology
1
90
How do #Korean #oncologists use #radiotherapy for recurrent #OvarianCancer? A survey of 116 gynecologic and radiation oncologists reveals differences in goals, patient selection, and SABR use, highlighting the need for standardized guidelines.
Read more: ejgo.org/DOIx.php?id=10.3802…
117
Does adjuvant radiation modality matter in FIGO stage I clear cell & papillary serous #EndometrialCancer?
SEER analysis shows #brachytherapy associated with superior survival vs. #EBRT (HR 0.44 at 5 yrs; 0.40 at 10 yrs), with 5-yr OS ~81%
👉Read more: ejgo.org/DOIx.php?id=10.3802…
259
📢Article Alert
How long does chemotherapy-induced peripheral #neuropathy last in #GynecologicCancer survivors?
New evidence suggests symptoms improve but may not fully resolve even after 5 years.
Full study ejgo.org/DOIx.php?id=10.3802…
#GynecologicOncology #CIPN
Journal of Gynecologic Oncology retweeted
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
ascopubs.org/doi/10.1200/OP-…




















